Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30;2(4):e000208. doi: 10.1161/JAHA.113.000208.
Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE, Northwick Park Heart Study II . Northwick Park Heart Study II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta. 2003;1639(3):203-12.
Lanza FL, Sontag SJ, Ciociola AA, Sykes DL, Heath AT, McSorley DJ. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter. 1998 Sep;3(3):212-21.
Graham DY, Breiter JR, Ciociola AA, Sykes DL, McSorley DJ. An alternative non-macrolide, non-imidazole treatment for curing helicobacter pylori and duodenal ulcers: ranitidine bismuth citrate plus amoxicillin. Helicobacter. 1998 Jun;3(2):125-31.